Literature DB >> 28970218

Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?

Marie Holmqvist1, Lotta Ljung2, Johan Askling1.   

Abstract

OBJECTIVE: To investigate if, and when, patients diagnosed with rheumatoid arthritis (RA) in recent years are at increased risk of death.
METHODS: Using an extensive register linkage, we designed a population-based nationwide cohort study in Sweden. Patients with new-onset RA from the Swedish Rheumatology Quality Register, and individually matched comparators from the general population were followed with respect to death, as captured by the total population register.
RESULTS: 17 512 patients with new-onset RA between 1 January 1997 and 31 December 2014, and 78 847 matched general population comparator subjects were followed from RA diagnosis until death, emigration or 31 December 2015. There was a steady decrease in absolute mortality rates over calendar time, both in the RA cohort and in the general population. Although the relative risk of death in the RA cohort was not increased (HR=1.01, 95% CI 0.96 to 1.06), an excess mortality in the RA cohort was present 5 years after RA diagnosis (HR after 10 years since RA diagnosis=1.43 (95% CI 1.28 to 1.59)), across all calendar periods of RA diagnosis. Taking RA disease duration into account, there was no clear trend towards lower excess mortality for patients diagnosed more recently.
CONCLUSIONS: Despite decreasing mortality rates, RA continues to be linked to an increased risk of death. Thus, despite advancements in RA management during recent years, increased efforts to prevent disease progression and comorbidity, from disease onset, are needed. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  arthritis; early rheumatoid arthritis; outcomes research

Mesh:

Year:  2017        PMID: 28970218     DOI: 10.1136/annrheumdis-2017-212131

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA.

Authors:  Xanthe Me Matthijssen; Tom Wj Huizinga; Ellis Niemantsverdriet; Annette Hm van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2019-06-22       Impact factor: 19.103

Review 2.  Morning Stiffness in Elderly Patients with Rheumatoid Arthritis: What is Known About the Effect of Biological and Targeted Agents?

Authors:  Chi Chiu Mok
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

Review 3.  Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.

Authors:  Chiara Crotti; Elena Agape; Andrea Becciolini; Martina Biggioggero; Ennio Giulio Favalli
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 4.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

Review 5.  Global epidemiology of rheumatoid arthritis.

Authors:  Axel Finckh; Benoît Gilbert; Bridget Hodkinson; Sang-Cheol Bae; Ranjeny Thomas; Kevin D Deane; Deshiré Alpizar-Rodriguez; Kim Lauper
Journal:  Nat Rev Rheumatol       Date:  2022-09-06       Impact factor: 32.286

6.  Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.

Authors:  Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova
Journal:  Rheumatol Int       Date:  2019-05-03       Impact factor: 2.631

Review 7.  [Biologics and further new drugs for rheumatic diseases since 2000].

Authors:  K Krüger
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

8.  Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months.

Authors:  Helen V Udachkina; Diana S Novikova; Tatiana V Popkova; Irina G Kirillova; Evgenia I Markelova
Journal:  Rheumatol Int       Date:  2018-05-11       Impact factor: 2.631

9.  Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.

Authors:  Benedicte Delcoigne; Lotta Ljung; Sella A Provan; Bente Glintborg; Merete Lund Hetland; Kathrine Lederballe Grøn; Ritva Peltomaa; Heikki Relas; Carl Turesson; Bjorn Gudbjornsson; Brigitte Michelsen; Johan Askling
Journal:  Ann Rheum Dis       Date:  2022-03-22       Impact factor: 27.973

10.  Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis.

Authors:  Sarah Twigg; Elena Nikiphorou; Jackie L Nam; Laura Hunt; Kulveer Mankia; Peta Elizabeth Pentony; Jane E Freeston; Ai Lyn Tan; Paul Emery
Journal:  Front Med (Lausanne)       Date:  2018-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.